InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,731.86
(
0.46%
)
US TECH 100
19,512.00
(
0.82%
)
Dow Jones
42,039.29
(
0.66%
)
Brent Oil
73.03
(
-1.33%
)
Bitcoin
69,044.25
(
-1.65%
)
Post# of 253509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120655
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 89977

Friday, 08/20/2010 6:10:58 AM

Friday, August 20, 2010 6:10:58 AM

Post# of 253509
Sigmapharm Laboratories files Paragraph-IV challenge for GILD’s Hepsera:

http://finance.yahoo.com/news/Gilead-Sciences-Announces-bw-974569144.html?x=0&.v=1

The obvious question is: Why bother? For all practical purposes, Hepsera has been superseded by Viread. Even if Sigmapharm prevails in the patent litigation, by the time the 30-month Hatch-Waxman stay expires, US Hepsera sales will not amount to much.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up